Kindstar Globalgene Technology, Inc.
9960.HK
Hong Kong Stock Exchange0.98
HKD
+0.03
- -
Kindstar Globalgene Technology, Inc.
9960.HK
(Hong Kong Stock Exchange)
Recent
price
0.98
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Kindstar Globalgene Technology, Inc. (9960.HK) operates as a leading provider of clinical esoteric testing services in China, offering advanced diagnostic solutions for hematology, genetic diseases and rare diseases, gynecology and maternity-related testing, infectious diseases, neurology, oncology, routine testing, scientific research services, and contract research organization services; its laboratory platforms include flow cytometry, cytogenetic analysis, medical genomics, molecular biology, hematopathology, mass spectrometry, pathology, clinical immunology, microbiology, and scientific research testing. The company delivers over 3,800 testing items, including more than 2,300 for blood system diseases such as leukemia and lymphoma, over 400 for genetic and rare diseases, 34 gynecology-related tests supported by technologies like NGS and mass spectrometry, over 200 for infectious diseases covering tuberculosis and fungal infections, over 100 for neurology conditions like autoimmune encephalitis, over 400 for oncology applications targeting lung, breast, colorectal, and other cancers, and routine biochemical, immunological, hematological, and microbiological tests. Founded in 2003 and headquartered in Wuhan with major laboratories in Beijing, Shanghai, Tianjin, Chengdu, Urumqi, and additional facilities, Kindstar Global serves over 3,000 hospitals across 31 provinces, including more than 1,000 tertiary hospitals, as well as pharmaceutical companies and research institutions. Recent developments include the January 2025 completion of the acquisition of Guangzhou AnchorDx Medical Co., Ltd. and Guangzhou Kangchengweiye Biotechnology Co., Ltd., enhancing solid tumor testing capabilities with products like PulmoSeek for lung cancer early screening and UriFind for urothelial carcinoma, both advancing in regulatory filings; angel investment in Wuhan Tuoruijing in January 2025 for ultra-multiplex PCR platforms in hematology, infectious diseases, and oncology; joint venture with U.S.-based Biostate AI in June 2025 to form Wuhan Baisheng Intelligence for AI-driven RNA multi-omics diagnostics targeting autoimmune diseases, cancers, diabetes, and transplantation; expanded stake to 40% in Huaxi Kindstar Health Technology in November 2025 via subsidiary; and over 20% growth in self-operated esoteric testing reagents sales in the first half of 2025, with new R&D projects in CAR-T monitoring, MRD detection, and immune repertoire products like Lymscan. The company listed on the Hong Kong Stock Exchange Main Board in July 2021 and maintains operations primarily in the People's Republic of China through its investment holding structure incorporated in the Cayman Islands.